We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Proteinuria Contributes to Greater CKD Progression Risk in Men

By LabMedica International staff writers
Posted on 29 Aug 2019
Print article
Image: A photomicrograph showing numerous completely sclerotic glomeruli and severe chronic tubulointerstitial nephritis from a patient with end-stage kidney disease (Photo courtesy of Dr. Jian-Hua Qiao, MD, FCAP).
Image: A photomicrograph showing numerous completely sclerotic glomeruli and severe chronic tubulointerstitial nephritis from a patient with end-stage kidney disease (Photo courtesy of Dr. Jian-Hua Qiao, MD, FCAP).
Older men with chronic kidney disease had a 50% increased risk for progression to end-stage kidney disease (ESKD) compared with women and this may be the result of higher levels of proteinuria.

End stage kidney disease is the last stage (stage five) of chronic kidney disease (CKD). This means kidneys are only functioning at 10% to 15% of their normal capacity. When kidney function is this low, they cannot effectively remove waste or excess fluid from the blood.

A team of scientists working with the University of Campania (Naples, Italy) evaluated the impact of gender on CKD progression, and conducted a pooled analysis of four observational cohort studies, which included a total of 2,335 men and women with an eGFR of less than 45 mL/min/1.73m2 (mean age, 67.1 years; mean eGFR, 26.9 mL/min/1.73m2). While age, systolic blood pressure and use of renin-angiotensin system inhibitors were similar between men and women, women had a lower median proteinuria (protein excretion, 0.45 g/d) compared with men (0.69 g/d).

The team reported that during a median follow-up of 4.2 years, 757 developed ESKD (59.4% men) and 471 died (58.4% men). The adjusted risks for ESKD and mortality were higher in men (Hazard Ratios (HRs) of 1.50 and 1.30 respectively). This finding was consistent across CKD stages. They observed a significant interaction between gender and proteinuria, with the risk for ESKD in men being significantly greater than for women at a level of proteinuria of ∼0.5 g/d or greater. When examining eGFR, they concluded that the slope of decline in eGFR was steeper in men than in women and that the difference in slopes between men and women was progressively larger with proteinuria less than 0.50 g/d.

The team concluded that data obtained from patients with clinical features consistent with the epidemiologic pattern of the present CKD population worldwide, namely advanced age and high prevalence of diabetes and cardiovascular disease. Still, although their study had some limitations, the results derive from a population of referred white patients with CKD and therefore findings may not hold true for other ethnic groups. Despite this limitation, proteinuria levels may modify the association between sex and renal risk.

Roberto Minutolo, MD, PhD, a Professor of Nephrology, and lead author of the study said, “The importance of sexual dimorphisms has been observed for hypertension and cardiovascular complications with regard to disease presentation, likelihood of progression to advanced phases and response to treatment. To date, the impact of sex on CKD remains poorly defined. In this setting, the mechanisms underlying the observed sex disparity in the epidemiology of kidney diseases have not been fully elucidated.” The study was published on August 10, 2019, in the American Journal of Kidney Diseases.

Related Links:
University of Campania

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
HPV Molecular Controls
ZeptoMetrix® HPV Type 16, 18, 45 & 68 Molecular Controls
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.